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.
INTRODUCTION 
 
          It is estimated that about one third of the world’s population is 
infected with Mycobacterium tuberculosis 1. Not all people infected have the 
disease, and most of them are adults. Tuberculosis (TB), however, remains 
an under-diagnosed and neglected entity in children. A total of 8.3 million 
new cases of TB were reported worldwide in 2000, of which an estimated 
11% cases were children and the reported percentage of all TB cases 
occurring in children varied from 3% to more than 25% in different 
countries.2,3 
           Infection with M. tuberculosis usually results from inhalation into the 
lungs of infected droplets produced by someone who has pulmonary TB and 
who is coughing. The source of infection of most children is an infectious 
adult in their close environment (usually the household). This exposure leads 
to the development of a primary parenchymal lesion (Ghon focus) in the 
lung with spread to the regional lymph node(s). The immune response 
(delayed hypersensitivity and cellular immunity develops about 4–6 weeks 
after the primary infection. In most cases, the immune response stops the 
multiplication of M.tuberculosis bacilli at this stage. However, a few 
dormant bacilli may persist. A positive tuberculin skin test (TST) would be 
the only evidence of infection. 
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          Progression of disease occurs by: (i) extension of the primary focus 
with or without cavitation, (ii) the effects of pathological processes caused 
by the enlarging lymph nodes, or (iii) lymphatic and/or haematogenous 
spread. Children who develop disease usually do so within 2 years following 
exposure and infection, i.e. they develop primary TB. A small proportion of 
children with TB (generally older children) develop post-primary TB either 
due to reactivation, after a latent period, of dormant bacilli acquired from a 
primary infection or by reinfection.            
          The Revised National Tuberculosis Control Programme (RNTCP)6, 
which was initiated in 1997, included the treatment of pediatric cases 
according to body weight. The regimen recommended for treating the 
pediatric cases had been 2R3H3Z3 / 4R3H3 for children less than 6 years of 
age. For all children above 6 years, the same regimen was recommended as 
for adults.  
         In early 2004, in consultation with Indian Academy of Pediatrics, the 
recommendations were revised whereby Ethambutol was included for 
treatment of pediatric cases even under 6 years of age.The Programme had 
been getting feedback in regard to the difficulty in administering the drugs 
to smaller children as the available formulations needed to be broken up to 
meet the patients’ individual weights.  
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          To overcome these problems, RNTCP in consultation with IAP, has 
taken steps to make the pediatric drugs available in patient-wise boxes 
(PWBs) similar to those supplied for adult patients under RNTCP. With the 
availability of pediatric PWBs, all new pediatric patients diagnosed and 
registered for treatment under RNTCP, would be initiated on pediatric 
patient wise boxes. This will enable optimum dosage for the patients, 
without resorting to further breaking of the tablets,as per the respective 
weight bands.  
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.
 
ETIOPATHOGENESIS 
ETIOLOGY 
         There are 5 closely related mycobacteria in the M. tuberculosis 
complex: M. tuberculosis, M. bovis, M. africanum, M. microti, and                   
M. canetti. M. tuberculosis is the most important cause of tuberculosis 
disease in humans. The tubercle bacilli are non-spore-forming, nonmotile, 
pleomorphic, weakly gram-positive curved rods 2–4 μm long. They may 
appear beaded or clumped in stained clinical specimens or culture media.8  
 
They are obligate aerobes that grow in synthetic media containing 
glycerol as the carbon source and ammonium salts as the nitrogen source 
(Loewenstein-Jensen culture media). These mycobacteria grow best at 37–
41°C, produce niacin, and lack pigmentation. A lipid-rich cell wall accounts 
for resistance to the bactericidal actions of antibody and complement. A 
hallmark of all mycobacteria is acid fastness—the capacity to form stable 
mycolate complexes with arylmethane dyes such as crystal violet, 
carbolfuchsin, auramine, and rhodamine. Once stained, they resist 
decoloration with ethanol and hydrochloric or other acids12. 
 
TRANSMISSION  
Transmission of M. tuberculosis is person to person, usually by 
airborne mucus droplet nuclei, particles 1–5 μm in diameter that contain M. 
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tuberculosis. Transmission rarely occurs by direct contact with an infected 
discharge or a contaminated fomite. The chance of transmission increases 
when the patient has an acid-fast smear of sputum, an extensive upper lobe 
infiltrate or cavity, copious production of thin sputum, and severe and 
forceful cough. Environmental factors, especially poor air circulation, 
enhance transmission. 
 
Most adults no longer transmit the organism within several days to 2 
weeks after beginning adequate chemotherapy, but some patients remain 
infectious for many weeks. Young children with tuberculosis are rarely 
infectious. Tubercle bacilli are sparse in the endobronchial secretions of 
children with pulmonary tuberculosis, and cough is often absent or lacks the 
tussive force required to suspend infectious particles of the correct size. 
However, children and adolescents with adult-type cavitary or 
endobronchial pulmonary tuberculosis can transmit the organism39. 
 
PATHOGENESIS  
          The primary complex of tuberculosis includes local infection at the 
portal of entry and the regional lymph nodes that drain the area. The lung is 
the portal of entry in >98% of cases. The tubercle bacilli multiply initially 
within alveoli and alveolar ducts where most are killed, but some survive 
within nonactivated macrophages, which carry them through lymphatic 
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vessels to the regional lymph nodes. When the primary infection is in the 
lung, the hilar lymph nodes usually are involved, although an upper lobe 
focus may drain into paratracheal nodes. The tissue reaction in the lung 
parenchyma and lymph nodes intensifies over the next 2–12 wk as the 
organisms grow in number and tissue hypersensitivity develops. 
 
 The parenchymal portion of the primary complex often heals 
completely by fibrosis or calcification after undergoing caseous necrosis and 
encapsulation. Occasionally, this portion continues to enlarge, resulting in 
focal pneumonitis and pleuritis. Intense caseation results in cavity formation. 
 
 Despite fibrosis and encapsulation in the infected regional lymph 
nodes, viable M. tuberculosis can persist for decades within these foci. In 
most cases of initial tuberculosis infection the lymph nodes remain normal 
in size. However, hilar and paratracheal lymph nodes that enlarge 
significantly as part of the host inflammatory reaction may encroach on a 
regional bronchus, resulting in hyperinflation in the distal lung segmentdue 
to partial obstruction or atelectasis due to complete obstruction. Inflamed 
caseous nodes can erode through bronchial walls, causing endobronchial 
tuberculosis or a fistula tract. The combination of pneumonitis and 
atelectasis, has been called a collapse-consolidation or segmental lesion. 
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LYMPH NODE DISEASE 
Tuberculosis of the superficial lymph nodes, often referred to as 
scrofula, is the most common form of extrapulmonary tuberculosis in 
children. Historically, scrofula was usually caused by drinking 
unpasteurized cow's milk laden with M. bovis. Most current cases occur 
within 6–9 mo of initial infection by M. tuberculosis, although some cases 
appear years later. The tonsillar, anterior cervical, submandibular, and 
supraclavicular nodes become involved secondary to extension of a primary 
lesion of the upper lung fields or abdomen.. Systemic signs and symptoms 
other than a low-grade fever are usually absent. The tuberculin skin test is 
usually reactive, but the chest radiograph is normal in 70% of cases. The 
onset of illness is occasionally more acute, with rapid enlargement of lymph 
nodes, high fever, tenderness, and fluctuance. 
 
Tuberculous lymphadenitis can usually be diagnosed by fine-needle 
aspiration of the node and responds well to antituberculosis therapy, 
although the lymph nodes do not return to normal size for months or even 
years. Surgical removal is not always necessary, and must be combined with 
antituberculous medication because the lymph node disease is but one part 
of a systemic infection. 
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DIAGNOSIS OF TB IN CHILDREN 
The diagnosis of TB in children relies on careful and thorough 
assessment of all the evidence derived from a careful history, clinical 
examination and relevant investigations, e.g. TST, chest X-ray (CXR) and 
sputum smear microscopy. Most children with TB have pulmonary TB. 
Although bacteriological confirmation of TB is not always feasible, it should 
be sought whenever possible, e.g. by sputum microscopy for children with 
suspected pulmonary TB who are old enough to produce a sputum sample. 3 
 
RECOMMENDED APPROACH FOR DIAGNOSIS OF TB IN 
CHILDREN  
 
1. Careful history (including history of TB contact and symptoms 
consistent with TB). The following points concerning contact are of 
importance for diagnosing TB in children. 
 All children aged 0–4 years and children aged 5 years and above who 
are symptomatic, who have been in close contact with a smear-
positive TB case, must be screened for TB. 
 When any child (aged less than 15 years) is diagnosed with TB, an 
effort should be made to detect the source case (usually an adult with 
sputum smear-positive pulmonary TB) and any other undiagnosed 
cases in the household. 
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 If a child presents with infectious TB, child contacts must be sought 
and screened, as for any smear-positive source case. Children should 
be regarded as infectious if they have sputum smear-positive 
pulmonary TB or cavitary TB on CXR. 
b. Symptoms.  
In most cases, children with symptomatic TB develop chronic 
symptoms. The commonest are: 
 Chronic cough 
An unremitting cough that is not improving and has been present for 
more than 21 days. 
 Fever 
Body temperature of >38 °C for 14 days, after common causes such 
as malaria or pneumoniahave been excluded. 
 Weight loss or failure to thrive 
In addition to asking about weight loss or failure to thrive, it is 
necessary to look at the child's growth chart. 
 
The specificity of symptoms for the diagnosis of TB depends on how 
strict the definitions of the symptoms are. 
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2. Clinical examination (including growth assessment) 
There are no specific features on clinical examination that can 
confirm that the presenting illness is due to pulmonary TB. Some signs, 
although uncommon, are highly suggestive of extrapulmonary TB (i.e. TB 
of organs other than the lungs). Other signs are common and should prompt 
an investigation into the possibility of childhood TB.  
 
Documented weight loss or failure to gain weight, especially after 
being treated in a nutritional rehabilitation programme, is a good indicator of 
chronic disease in children, of which TB may be the cause. 
3. Tuberculin skin test 
A positive TST occurs when a person is infected with M. tuberculosis, 
but does not necessarily indicate disease. However, the TST can also be 
used as an adjunct in diagnosing TB in children with signs and symptoms of 
TB and when used in conjunction with other diagnostic tests. There are a 
number of TSTs available, but the TST using the Mantoux method is the 
recommended test. 
4. Bacteriological confirmation whenever possible 
It is always advisable to confirm diagnosis of TB in a child using 
whatever specimens and laboratory facilities are available. Appropriate 
specimens from the suspected sites of involvement should be obtained for 
microscopy and, where facilities and resources are available, for culture (and 
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also histopathological examination). Appropriate clinical samples include 
sputum, gastric aspirates and certain other material (e.g. lymph node biopsy 
or any other material that is biopsied). Fine-needle aspiration of enlarged 
lymph glands – for both staining of acid-fast bacilli and histology – has been 
shown to be a useful investigation, with a high bacteriological yield. In 
addition to increasing the yield of confirmed TB cases, mycobacterial 
culture is the only way to differentiate M. tuberculosis from other 
nontuberculous mycobacteria.  
Common ways of obtaining samples for smear microscopy include 
the following. 
a. Expectoration 
 Sputum should always be obtained in adults and older children (10 
years of age or older) who are pulmonary TB suspects. Among younger 
children, especially children under 5 years of age, sputum is difficult to 
obtain and most children are sputum smear-negative. However, in children 
who are able to produce a specimen, it is worth sending it for smear 
microscopy (and mycobacterial culture if available). Bacterial yields are 
higher in older children (more than 5 years of age) and adolescents, and in 
children of all ages with severe disease. As with adult TB suspects, three 
sputum specimens should be obtained: an on-the-spot specimen (at first 
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evaluation), an early morning specimen and a second on-the-spot specimen 
(at a follow-up visit). 
 
b. Gastric aspiration 
Gastric aspiration using a nasogastric feeding tube can be performed 
in young children who are unable or unwilling to expectorate sputum. 
Gastric aspirates should be sent for smear microscopy and mycobacterial 
culture. A gastric aspirate should be obtained on each of three consecutive 
mornings. 
 
c. Sputum induction 
Several recent studies have found that sputum induction is safe and 
effective in children of all ages and the bacterial yields are as good as or 
better than for gastric aspirates. However, training and specialized 
equipment are required to perform this procedure properly. 
In developing and improving laboratory services for TB diagnosis, the 
priority is to ensure there is a network of quality controlled microscopy 
laboratories for staining acid-fast bacilli in clinical samples, most often 
sputum. 
5. Investigations relevant for suspected pulmonary TB and suspected 
extrapulmonary TB 
a. Suspected pulmonary TB 
  
13
.
 Chest radiography is useful in the diagnosis of TB in children. In the 
majority of cases, children with pulmonary TB have CXR changes 
suggestive of TB. The commonest picture is that of persistent opacification 
in the lung together with enlarged hilar or subcarinal lymph glands. A 
miliary pattern of opacification in HIV-uninfected children is highly 
suggestive of TB. Patients with persistent opacification which does not 
improve after a course of antibiotics should be investigated for TB. 
Adolescent patients with TB have CXR changes similar to adult patients 
with large pleural effusions and apical infiltrates with cavity formation being 
the most common forms of presentation. 
 
 Adolescents may also develop primary disease with hilar adenopathy 
and collapse lesions visible on CXR. Good-quality CXRs are essential for 
proper evaluation. CXRs should preferably be read by a radiologist or a 
health-care worker trained in their reading. A practical guide for interpreting 
CXRs has been developed. 
 
b. Suspected extrapulmonary TB 
 In most of these cases, TB will be suspected from the clinical picture 
and confirmed by histology or other special investigations. 
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Common forms of extrapulmonary TB in children 
Site   Practical approach to diagnosis 
Peripheral lymph nodes (esp. cervical) Lymph node biopsy   
or    
Fine needle aspiration 
Miliary TB (e.g. disseminated)                 Chest X-ray and lumbar puncture 
(to test for meningitis) 
TB meningitis                                            Lumbar puncture (and 
computerized tomography)      
Pleural effusion                                        Chest X-ray, pleural tap for 
(older children and adolescents)  
biochemical analysis (protein & 
glucose concentrations) cell count 
and culture 
Abdominal TB                                           Abdominal ultrasound and ascitic 
tap (e.g. peritoneal)                         
 
Standard case definitions of TB in children 
The diagnosis of TB refers to the recognition of an active case, i.e. a 
patient with symptomatic disease (due to M. tuberculosis infection). Beyond 
the diagnosis of TB disease, the type of TB case should also be defined to 
enable appropriate treatment to be given and the outcome of treatment 
evaluated. The case definition is determined by the: (i) site of disease, (ii) 
result of any bacteriological tests, (iii) severity of TB disease, and (iv) 
history of previous anti-TB treatment. All children with TB should be 
registered with the RNTCP as smear-positive pulmonary, smear-negative 
pulmonary TB or extrapulmonary TB, and as a new case or a previously 
treated case. Standard case definitions are provided below 
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Pulmonary TB, sputum smear-positive 
The criteria are: 
¾ two or more initial sputum smear examinations positive for acid-fast 
bacilli; or 
¾ one sputum smear examination positive for acid-fast bacilli plus CXR 
abnormalities consistent with active pulmonary TB, as determined by a 
clinician; or 
¾ one sputum smear examination positive for acid-fast bacilli plus sputum 
culture positive for M.tuberculosis. 
 
Adolescents, or children of any age with complicated intrathoracic 
disease, are more likely to have sputum smear-positive pulmonary TB. 
 
Pulmonary TB, sputum smear-negative 
A case of pulmonary TB that does not meet the above definition for 
smear-positive pulmonary TB. Such cases include cases without smear 
results, which should be exceptional in adults but relatively more frequent in 
children. In keeping with good clinical and public health practice, diagnostic 
criteria for sputum smear-negative pulmonary TB should include: 
¾ at least three sputum specimens negative for acid-fast bacilli; and 
¾ radiological abnormalities consistent with active pulmonary TB; and 
¾ no response to a course of broad-spectrum antibiotics; and 
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¾ decision by a clinician to treat with a full course of anti-TB 
chemotherapy. 
 
Extrapulmonary TB 
Children with only extrapulmonary TB should be classified under this 
case definition. Children who have both pulmonary and extrapulmonary TB 
should be classified under the case definition of pulmonary TB. 
 
Anti-TB treatment in children 
Background 
The main objectives of anti-TB treatment are to: 
1. Cure the patient of TB (by rapidly eliminating most of the bacilli); 
2. Prevent death from active TB or its late effects; 
3. Prevent relapse of TB (by eliminating the dormant bacilli); 
4. Prevent the development of drug resistance (by using a 
combination of drugs); 
5. Decrease TB transmission to others. 
 
 Children usually have paucibacillary pulmonary disease (low 
organism numbers), as cavitating disease is relatively rare (about 6% of 
cases or fewer) in those under 13 years of age (the majority of the organisms 
in adult-type disease are found in the cavities). In contrast, children develop 
extrapulmonary TB more often than adults do. Severe and disseminated TB 
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(e.g. TB meningitis and miliary TB) occur especially in young children (less 
than 3 years old). Both the bacillary load and the type of disease may 
influence the effectiveness of treatment regimens. Treatment outcomes in 
children are generally good, even in young and immunocompromised 
children who are at higher risk of disease progression and disseminated 
disease, provided that treatment starts promptly. There is a low risk of 
adverse events associated with use of the recommended treatment regimens 
 
Recommended treatment regimens 
Anti-TB treatment is divided into two phases: an intensive phase and 
a continuation phase. The purpose of the intensive phase is to rapidly 
eliminate the majority of organisms and to prevent the emergence of drug 
resistance. This phase uses a greater number of drugs than the continuation 
phase. The purpose of the continuation phase is to eradicate the dormant 
organisms. Fewer drugs are generally used in this phase because the risk of 
acquiring drug resistance is low, as most of the organisms have already been 
eliminated 
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Management of Pediatric Tuberculosis Under the Revised National 
Tuberculosis Control Programme 
DOTS is the recommended strategy for treatment of TB and all Pediatric TB 
and all Pediatric TB patients should be registered under RNTCP22,37.  
Category of 
treatment Type of patients TB treatment regime 
  Intensive Phase Continuation Phase 
Category I • New sputum smear positive 
PTB 
• Seriously ill sputum smear 
negative PTB with extensive 
parenchymal involvement 
(acute military, segmental/
lobar opacity) 
• Seriously ill extra-
pulmonary TB includes 
disseminated/ military TB, 
TB pericarditis, TB 
peritonitis and intestinal TB, 
bilateral or extensive 
pleurisy, genitor-urinary 
tract TB, bone and joint TB.
2H3R3Z3E3 4H3R3 
Category I • CNS TB (meningitis, 
tuberculoma of brain, spinal 
TB with or without 
neurological complications 
and other part of nervous 
system) 
2H3R3Z3S3 6-7H3R3 
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Category II • Sputum smear-positive 
relapse, (with evidence of 
tubercular features) 
• Sputum smear-positive 
treatment failure, (with 
evidence of tubercular 
features) 
• Sputum smear-positive 
treatment after default, (with 
evidence of tubercular 
features) 
2S3H3R3Z3E3/ 
1 H3R3Z3E3 
5 H3R3E3 
Category III • Sputum smear-negative and 
Extra-pulmonary TB, not 
seriously ill (TB adenitis, 
mediastinal 
lymphadenopathy, skin TB 
and not seriously ill 
abdominal TB) 
2H3R3Z3 4H3R3 
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REVIEW OF LITERATURE 
The literature review was done to understand the current status of 
clinical profile of tuberculosis in children, the treatment outcome and 
adverse effects associated with short course chemotherapy. 
 
Age distribution 
 Vimlesh seth et al24 has shown that age distribution was equal in all 
age groups except during infancy when it was rare. 
 
 Ileana Puiu et al16 has shown that Tubercular lymphadenitis is more 
common in age group of 10 to 16 (39.1%)    followed by 6 to 10 (25.2%) 
 
 Polesky 20 and co study shows that TB adenitis is more common in 
age group 10 to19 
 
 Sex distribution 
 Vimlesh seth et al 24 study shows that sex ratio indicates a male 
preponderance with male to female in the ratio of 1.5: 1 (67 : 46). 
 
Ileana Puiu et al16  has shown that  the distribution of the cases 
according to sex reveals a slight predominance of females (51.6%), as 
compared to males (48.4%) 
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Jhaa et al19 study has shown a slight female preponderance 1:1.3  
Dandapat et al18 has also shown a slight female preponderance 1:1.2 
Castro et al17 study also found a female preponderance 1:1.3. 
 
Mantoux positivity 
 A study conducted at ICH Chennai Vijayasekaran et al 35 has shown 
that the positivity of Mantoux in lymph node tuberculosis (53%) 
 
 A study conducted at AIIMS by Vimlesh seth et al 24 shows that 
Mantoux test was positive in 96 (85%) children 
Ileana Puiu et al 16 study has shown a 87.3% mantoux positivity. 
Jhaa et al19  also shows a higher mantoux positivity at 95%. 
Dandapat et al18   study shows that mantoux positivity is seen in 94%. 
          In Castro et al  17study mantoux positivity is 74%. 
 
Malnutrition  
 Vimlesh seth et al 24 study has shown that malnutrition is present in 
88% of patients. 
 Balaji et al 36 study conducted at ICH Madurai has shown a significant 
correlation of malnutrition with TB adenitis 
 
Contact history  
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 A study conducted at ICH Chennai by Vijayasekaran et al 35has 
shown that contact positivity is seen in 30.4% of patients. 
 A study conducted at AIIMS by Vimlesh seth et al 24 has shown a 
positive contact history in 19% of children. 
 
 Ileana Puiu et al 16 study has a positive contact history in 87.3% of 
children. 
 
Radiological changes 
          Ileana Puiu et al16 study has abnormal radiological findings in 21.8% 
of TB adenitis patients. 
          Jhaa et al19 study shows abnormal radiological features in 16% of 
children with TB adenitis. 
          Polesky et al 20 study has shown abnormal radiological feature in 38% 
of children with TB adenitis. 
          Dandapat et al 18 35% of children with TB adenitis had abnormal 
radiological findings. 
          Castro et al 17 study has abnormal radiological finding in 18% of 
children with TB adenitis. 
 
Anemia  
          Ileana Puiu et al 16 study has shown anemia in 55.2% of children with 
TB adenitis. 
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Adverse symptoms 
          Al Dossary et al 25 has shown that adverse events are seen in 1.2 % of 
children on DOTS. 
          Te Water Naude et al40 study has shown that none of the children had 
adverse events with DOTS. 
          In Tsakilidis D, et al 41 study none of the child had any adverse events 
taking DOTS. 
 
Treatment outcome 
CK Indumathi et al  42  study conducted at St.John’s Medical College 
Hospital Bangalore has shown a overall cure rate of 95% including  97% 
cure rate in extra pulmonary TB and 94 % in pulmonary TB 
Biddulph J et al 26 study has 7 relapse cases out of 373 cases 
Gocmen A, et al 43 has 1 relapse case out of 130 cases 
         Tsakilidis D, et al 41 had no cases of relapse out of 36 children with TB  
 
Guidelines for use of Pediatric Patient Wise boxes under the Revised 
National Tuberculosis Control Programme  
 
The new formulations to be used in RNTCP are: 
 Rifampicin – 75 /150 mg 
 Isoniazid – 75 /150 mg 
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 Ethambutol – 200 /400 mg 
 Pyrazinamide – 250 / 500 mg 
For the purpose of treatment, the pediatric population is divided into four 
weight bands: 
 6 – 10 kgs 
 11 – 17 kgs 
 18 – 25 kgs 
 26 – 30 kgs 
 
          The anti–TB drugs for pediatric patients will be available in the form 
of 2 generic patient wise boxes i.e. Product Code 13 and Product Code 14. 
Product Code 15 and 16 would be available for the prolongation of the 
intensive phase, if required and also to facilitate conversion of the boxes into 
Category II and for reconstitution, if required. 
The composition of product codes 13 to 16 is given below: 
 
Product Code 13 - Treatment box for pediatric weight band category (6-10 
Kg). Each treatment box containing 24 Combi-packs of Schedule5 in one 
pouch and 18 multi-blister calendar Combi-pack of Schedule-6 in another 
pouch.The intensive phase consists of Isoniazid, Rifampicin, Pyrazinamide 
and Ethambutol to be given under direct observation thrice a week on 
alternate days for 2 months (24 doses). 
  
25
.
The continuation phase consists of 4 months (18 weeks; 54 doses) of 
Isoniazid and Rifampicin given thrice a week on alternate days - the first 
dose of every weekly blister being directly observed.  
 
Product Code 14 - Treatment box for pediatric weight band category (11-17 
Kg). Each treatment box containing 24 Combi-packs of Schedule-7 in one 
pouch and 18 multi-blister calendar Combi-pack of Schedule-8 in another 
pouch.  
 
The intensive phase consists of Isoniazid, Rifampicin, Pyrazinamide and 
Ethambutol to be given under direct observation thrice a week on alternate 
days for 2 months (24 doses). The continuation phase consists of 4 months 
(18 weeks; 54 doses) of Isoniazid and Rifampicin given thrice a week on 
alternate days - the first dose of every weekly blister being directly 
observed. 
 
Product Code 15 - Treatment box for prolongation of intensive phase of 
pediatric cases (6-10 kg and 18-25 kg). Each box containing 5 pouches and 
each pouch containing 12 blister Combi pack of Schedule-5.  
 
The pouch consists of Isoniazid, Rifampicin, Pyrazinamide and 
Ethambutol to be given under direct observation thrice a week on alternate 
days for 1 month (12 doses). 
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Product Code 16 - Treatment box for prolongation of intensive phase of 
pediatric cases (11-17 kg, 18-25 kg and 26-30 kg). Each box containing 5 
pouches and each pouch containing 12 blister Combipacks of Schedule-
7.Prolongation Pouch consists of Isoniazid, Rifampicin, Pyrazinamide and 
Ethambutol to be given under direct observation thrice a week on alternate 
days for 1 month (12 doses). 
 
The generic patient wise boxes, i.e. product code 13 and 14, according 
to weight band would be used for the pediatric patients in the following 
manner. 
• A patient weighing 6 – 10 kg would require 1 box of Product Code 13. 
• A patient weighing 11 – 17 kg would require 1 box of Product Code 14. 
• A patient weighing 18 – 25 kg would require 1 box of Product Code 13   
and 1 box of Product Code 14. 
• A patient weighing 26 - 30 kg would require 2 boxes of Product Code 14. 
 
The boxes have been designed to suit the requirements of Category I 
cases which are expected to dominate the patients belonging to pediatric age 
group. In case, any patients are to be placed on Category II or III, the 
following steps will have to be taken to convert the generic boxes into a 
Category II or III box: 
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Category II – Re-treatment Cases 
For children to be placed on Category II, PPs would be added for 
prolongation of IP. For the extra 1 month of CP, a PP would be added after 
removing the Pyrazinamide tablets from the PP. For the other 4 months of 
CP blisters, Ethambutol tablets will need to be added which can be used 
from the supplies of loose drugs under the Programme. 
  
SM Inj (750 mg) supplied under the programme shall be used for such 
patients and the dosage would be as per body weight. 
 
Category III cases 
For children who are to be put on Category III, the Ethambutol tablets 
will be removed from the IP blisters. 
 
Categorization and duration of therapy 
Categorization of pediatric cases will be as per RNTCP policy. The 
treatment regimens recommended under RNTCP are the same for adult and 
pediatric cases. The duration of therapy will be as per the treatment regimen. 
If required, the duration of therapy may be extended within the current 
RNTCP guidelines. 
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Use of Prolongation Pouches 
          Sputum positivity in the pediatric patients of lower weight categories 
is usually not found and it is also difficult to get a sputum sample in such 
children. However, for the older patients, sputum samples can be obtained 
and prolongation of intensive phase may be required. For such patients, 
prolongation pouches will be required. In addition, PP would also be 
required for the purpose of reconstitution of the PWBs of patients who have 
died, defaulted, transferred out and indoor patients who also would be 
treated under RNTCP using PPs. 
 
Chemoprophylaxis 
          Asymptomatic children under 6 years of age, exposed to an adult with 
infectious (smearpositive) tuberculosis from within the same household, are 
to be given 6 months of Isoniazid (5 mg per kg daily) as chemoprophylaxis. 
Loose tablets of INH 100 mg would continue to be supplied for this purpose 
as was previously done. 
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OBJECTIVES OF THE STUDY 
 
1. To assess the efficacy of DOTS using pediatric patient wise boxes under 
RNTCP in childhood tuberculosis- pulmonary and extra pulmonary (TB 
adenitis). 
 
2. To study the adverse effects associated with these fixed drug 
formulations of patient wise boxes. 
 
3. To study the clinical profile of TB adenitis in children.  
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METHODOLOGY 
 
This study was undertaken in the pediatric department of 
Govt.Kilpauk Medical College Hospital during the period of January 2008 
to june 2009. All the cases suspected to have tuberculosis are evaluated and 
if confirmed are registered in the TB clinic at Kilpauk Medical College.  
 
The study was commenced after formal approval of the ethical 
committee of our hospital. The study population included all the pediatric 
inpatients and outpatients confirmed of pulmonary tuberculosis and TB 
lymphadenitis. 
 
Inclusion Criteria: 
          All children upto 12 yrs of age diagnosed with pulmonary tuberculosis 
and TB adenitis. 
 
Exclusion Criteria: 
          1. Other forms of extra pulmonary tuberculosis. 
          2. HIV infected children 
          3. Relapse, default and failure cases 
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Maneuver: 
          All children admitted in the pediatric department of Kilpauk Medical 
college hospital who are diagnosed to have pulmonary tuberculosis and 
those with TB adenitis are registered in TB clinic at Kilpauk Medical 
College Chennai and are enrolled in the study group from January 2008 to 
December 2008. These children are started on Anti-Tubercular drugs based 
on recent RNTCP guidelines using pediatric patient wise boxes. These 
children are then followed up for a period of six months. 
 
 All children who had signs and symptoms suggestive of tuberculosis 
are admitted in the pediatric ward. A detailed history was obtained.  The 
history included the symptoms,duration, contact history, past history of 
tuberculosis, dietic history,immunization history especially BCG, and 
socioeconomic class. 
 
 A thorough clinical examination was done including the assessment 
of nutritional status. These children are subjected to the following 
investigations. 
1. Complete blood count – hemoglobin, total count, differential count, 
ESR, and peripheral smear study. 
2. Mantoux  
3. X-ray chest 
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4. Sputum / RGJ for AFB 
5. Liver function tests 
6. Fine Needle Aspiration Cytology in patients with lymphadenitis. 
7. HIV screening 
 The children are then diagnosed to have pulmonary tuberculosis based 
on WHO and RNTCP guidelines. They are then categorized according to the 
recent RNTCP guidelines. The Revised National Tuberculosis Control 
Programme (RNTCP), which was initiated in 1997, included the treatment 
of pediatric cases according to body weight. Until now, the same strategy 
has been continued. The regimen recommended for treating the pediatric 
cases had been 2R3H3Z3 / 4R3H3 for children less than 6 years of age. For 
all children above 6 years, the same regimen was recommended as for 
adults. 
 
 In early 2004, in consultation with Indian Academy of Pediatrics, the 
recommendations were revised whereby Ethambutol was included for 
treatment of pediatric cases even under 6 years of age. The Programme had 
been getting feedback in regard to the difficulty in administering the drugs 
to smaller children as the available formulations needed to be broken up to 
meet the patients’ individual weights.  
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 To overcome these problems, RNTCP in consultation with IAP, has 
taken steps to make the pediatric drugs available in patient-wise boxes 
(PWBs) similar to those supplied for adult patients under RNTCP. With the 
availability of pediatric PWBs, all new pediatric patients diagnosed and 
registered for treatment under RNTCP, would be initiated on pediatric 
patient wise boxes. This will enable optimum dosage for the patients, 
without resorting to further breaking of the tablets, as per the respective 
weight bands. Further, Rifampicin would be available in tablet form, which 
will enable easier swallowing of the drug by the pediatric patients. 
 
 In our study, these children are then followed up as per WHO 
guidelines. These children are followed up at 2,4,6 months of 
commencement of therapy. For those children who are sputum positive a 
repeat sputum was done on these occasions. For children who are diagnosed 
to have TB adenitis a repeat FNAC was done after 6 months. A decrease in 
size of the lymphnodes were also noted. A repeat X ray chest was taken for 
clearance of radiological changes after 6 months.  
 
 These children are monitored with serial measurement of weight and 
anthropometry. A repeat LFT and hemoglobin are done at the end of six 
months. 
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 They are also enquired about the relief of symptoms,any adverse 
effects, school attendance,compliance, difficulty in procurement of these 
drugs. 
 
 The treatment was considered successful in children who became 
sputum negative, with >2/3 of clearance of radiological changes, with   relief 
of symptoms and weight gain. For TB adenitis decrease in size and a normal 
FNAC finding in lymphnode was considered as successful treatment in the 
study. 
 
 All the statistical analysis was performed using the SPSS Software 
Version 10.0 package. Statistical tools such as chi-square test were used in 
the analysis. P-value of <0.005 is considered statistically significant. 
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RESULTS 
 112 children diagnosed with both pulmonary and TB adenitis were 
enrolled in the study, of which 82 cases were TB adenitis and 30 were 
pulmonary tuberculosis. The cases were registered in TB clinic and 
treatment started according to recent RNTCP guidelines using pediatric 
patient wise boxes. These children were the followed up for a period of 6 
months. The treatment outcome and the adverse effects of the drug are then 
analysed. 
Age distribution in TB adenitis 
The age distribution of cases in this study group are 
Age in yrs Frequency Percent Valid Percent Cumulative Percent 
<3 22 26.8 26.8 26.8 
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 Frequency Percent Valid Percent Cumulative Percent 
No  19 23.2 23.2 23.2 
Yes  63 76.8 76.8 100.0 
Total 82 100.0 100.0  
 
In this study out of the 82 children with TB adenitis 63 children 
76.8% are undernourished.  
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The adverse symptoms in different age groups are tabulated 
Crosstab 
   ADVERSE 
SYMPTOMS  
   No Yes Total 
AGE 
GROUP 
Less than 4 
yrs 
Count 21 1 22 
% of Total 25.6% 1.2% 26.8% 
4 to 6 yrs Count 12 1 13 
% of Total 14.6% 1.2% 15.9% 
7 to 9 yrs Count 17 4 21 
% of Total 20.7% 4.9% 25.6% 
10 to 12 yrs Count 20 6 26 
% of Total 24.4% 7.3% 31.7% 
 Total Count 70 12 82 
% of Total 85.4% 14.6% 100.0% 
 
Chi square  4.105   p Value  0.250 
  
This table shows that adverse symptoms are more common older age 
group children and younger children tolerate these drugs better than older 
ones.    
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Liver function test: 
          A baseline LFT was done before commencement of treatment which 
was normal in all the patients. A repeat LFT was done in all the patients 
during follow up. 
LFT During Follow Up 
Elevated Frequency Percent Valid Percent Cumulative Percent 
No  75 91.5 91.5 91.5 
yes 7 8.5 8.5 100.0 
Total 82 100.0 100.0  
  
 This table shows that LFT was elevated in 7 out of 82 cases. In all 
children there was only mild elevation of enzymes which did not require 
discontinuation of treatment. The serum bilirubin was normal in all the 
patients.  LFT became normal after 2 months after the completion of 
treatment. 
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Treatment outcome: 
          Out of 82 children diagnosed with TB adenitis all are proved with 
features of granulomatous adenitis in FNAC. A decrease in size of the 
lymphnode is seen in all patients. A repeat FNAC was done to confirm the 
successful treatment outcome. The result are tabulated as follows. 
 
FNAC 1 * FNAC 2 Crosstabulation 
   FNAC 2  
   negative positive Total 
FNAC 1 positive Count 80 2 82 
% of 
Total 
97.6% 2.4% 100.0% 
 Total Count 80 2 82 
% of 
Total 
97.6% 2.4% 100.0% 
 
         The treatment was successful in 80 out 82 children. Only 2 children 
had persistent features of TB adenitis in the study group. An additional 3 
months therapy was required in these children and an excision biopsy was 
done at the end of 9 months which did not show features of TB adenitis. 
  
46
.
 
Radiological features: 
          The radiological features are present in 23.2% of cases. Following 
treatment there is resolution of features in all the children. 
X RAY CHEST 1 * X RAY CHEST 2 Cross tabulation 
   
X RAY CHEST 2  
   Normal Total 
X RAY 
CHEST 1 
Normal Count 63 63 
% of Total 76.8% 76.8% 
Abnormal Count 19 19 
% of Total 23.2% 23.2% 
 Total Count 82 82 
% of Total 100.0% 100.0% 
 
Correlation of weight gain and hemoglobin with outcome: 
         All children enrolled in the study are monitored for weight gain during 
follow up. The hemoglobin level was also monitored. The levels at the end 
of treatment are correlated with the treatment outcome. The results are 
tabulated below. 
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Paired Samples Statistics 
 
  
Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 WEIGHT 1 17.9756 82 8.23869 .90981 
WEIGHT 2 20.9329 82 8.21838 .90757 
Pair 2 Hb 1 10.7341 82 1.26961 .14020 
Hb 2 11.8073 82 1.01747 .11236 
 
Paired Samples Correlations 
  N Correlation Sig. 
Pair 1 WEIGHT 1 & 
WEIGHT 2 
82 .979 .000 
Pair 2 Hb 1 & Hb 2 82 .819 .000 
   
                                                          p value 0.000   
  
 In our study as shown above there is a strong positive correlation 
(.979),between weight gain and outcome. This table also shows a positive 
correlation (0.819) between rise in hemoglobin.    
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Paired Samples Test 
  Paired Differences 
  Mean Std. Deviation 
Std. Error 
Mean 
Pair 1 WEIGHT 1 - 
WEIGHT 2 
-2.95732 1.67811 .18532 
Pair 2 Hb 1 - Hb 2 -1.07317 .72946 .08056 
 
Paired Samples Test 
  Paired Differences  
  95% Confidence 
Interval of the 
Difference  
  Lower Upper t df Sig. (2-tailed)
Pair 1 WEIGHT 1 - 
WEIGHT 2 
-3.32604 -2.58860 -15.958 81 .000 
Pair 2 Hb 1 - Hb 2 -1.23345 -.91289 -13.322 81 .000 
 
Treatment outcome in pulmonary tuberculosis: 
 
 In our study, out of 30 cases diagnosed as pulmonary tuberculosis, 5 
cases were sputum positive for AFB. All cases had abnormal radiological 
findings. Following treatment with category 1 of DOTS therapy using 
patient wise box , all the cases were cured at the end of therapy.  
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 All sputum positive children became sputum negative for AFB at the 
end of Intensive therapy. Radiological resolution is confirmed at the end of 
six months therapy. There was clearance of  x-ray findings in all the 
patients. 
 
Correlation of treatment outcome with weight gain and hemoglobin in 
pulmonary tuberculosis: 
         A correlation between weight gain and rise in hemoglobin levels 
following treatment with outcome is assessed. The results are as follows.          
 
Paired Samples Statistics 
  
Mean N Std. Deviation Std. Error Mean 
Pair 1 WEIGHT 1 16.87 30 7.181 1.311 
WEIGHT 2 18.93 30 7.353 1.342 
Pair 2 Hb1 10.88 30 1.213 .222 
Hb2 11.95 30 .947 .173 
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Paired Samples Correlations 
 
  N Correlation Sig. 
Pair 1 WEIGHT 1 & WEIGHT 2 30 .992 .000 
Pair 2 Hb1 & Hb2 30 .829 .000 
 
 
The above table indicates that a positive correlation 0.992 with a p 
value of 0.000 between weight gain and treatment outcome is stastically 
significant. 
 
Paired Samples Test 
 
  Paired Differences 
  
Mean Std. Deviation Std. Error Mean 
Pair 1 WEIGHT 1 - 
WEIGHT 2 
-2.067 .944 .172 
Pair 2 Hb1 - Hb2 -1.073 .680 .124 
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Paired Samples Test 
  Paired Differences  
  95% Confidence 
Interval of the 
Difference
 
  Lower Upper t df Sig. (2-tailed) 
Pair 1 WEIGHT 1 - 
WEIGHT 2 
-2.419 -1.714 -11.986 29 .000
Pair 2 Hb1 - Hb2 -1.327 -.819 -8.643 29 .000
 
The paired t test also shows a significant p value 0.000 
 
In our study during the follow up along with the nutritional 
assessment, all cases were enquired about the adverse symptoms, difficulty 
in drug procurement, compliance of the drug intake, school attendance in 
school going children.  
 
In our study we found that there were no difficulty in drug procurement as 
they were directly observed by a health care professional, the compliance 
was also very good as the parents were repeatedly educated about the 
treatment. School attendance was not affected considerably except in cases 
of sputum positive children 
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DISCUSSION 
 
 It is estimated that about one third of the world’s population is 
infected with Mycobacterium tuberculosis 1. Not all people infected have 
the disease, and most of them are adults. Tuberculosis (TB), however, 
remains an under-diagnosed and neglected entity in children. A total of 8.3 
million new cases of TB were reported worldwide in 2000, of which an 
estimated 11% cases were children and the reported percentage of all TB 
cases occurring in children varied from 3% to more than 25% in different 
countries. 
 
To combat this problem, The Revised National Tuberculosis Control 
Programme (RNTCP), which was initiated in 1997, included the treatment 
of pediatric cases according to body weight. The Programme had been 
getting feedback in regard to the difficulty in administering the drugs to 
smaller children as the available formulations needed to be broken up to 
meet the patients’ individual weights. To overcome these problems, RNTCP 
in consultation with IAP, has taken steps to make the pediatric drugs 
available in patient-wise boxes (PWBs) similar to those supplied for adult 
patients under RNTCP. 
 
Our aim of the study is to asses the treatment outcome of DOTS using 
patient wise boxes in childhood tuberculosis. Our study was done over a 
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period of one year from January 2008 to December 2008 and they are 
followed up for a period of six months and treatment outcome was assessed 
at the end of the study. The adverse effects associated with the drugs are also 
analysed. The clinical profile of TB adenitis was also analysed. 
 
In our study, 112 cases were enrolled of which 82 were TB adenitis 
and 30 cases were pulmonary tuberculosis. Treatment was successful in 80 
out of 82 cases of TB adenitis at the end of 6 months. Treatment was 
successful in all 30 cases of pulmonary tuberculosis. 
 
All cases of TB adenitis were diagnosed by FNAC and a repeat 
FNAC was done at the end of six months. The pulmonary tuberculosis was 
diagnosed based on radiological changes and sputum positivity for AFB. 
Out of 30 cases of pulmonary tuberculosis 5 cases were sputum positive for 
AFB. The results are as follows.  
 
In our study group TB adenitis was prevalent in all age groups and 
more common in children older than 9 years (31.7%). Vimlesh seth et al has 
shown that age distribution was equal in all age groups except during 
infancy when it was rare. Ileana Puiu et al has shown that Tubercular 
lymphadenitis is more common in age group of 10 to 16 (39.1%)    followed 
by 6 to 10 (25.2%). Polesky and co study shows that TB adenitis is more 
common in age group 10 to19.  
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In our study the there is a slight male preponderance in children with 
TB adenitis (56%) with females (44%) and sex ratio of 1:3. Vimlesh seth et 
al study also document a male preponderance with male to female in the 
ratio of 1.5: 1 (67: 46).Ileana Puiu et al has shown that the distribution of the 
cases according to sex reveals a slight predominance of females (51.6%), as 
compared to males (48.4%). Jhaa et al, Dandapat et al, Castro et al studies 
also found a female preponderance. 
 
The mantoux positivity rate in our study group with TB adenitis was 
42.6%.A study conducted at ICH Chennai  by Vijayasekaran et al has shown 
that the positivity of Mantoux in lymph node tuberculosis (53%). A study 
conducted at AIIMS by Vimlesh seth et al shows that Mantoux test was 
positive in 96 (85%) children. Ileana Puiu et al study has shown a 87.3% 
mantoux positivity .Jhaa et al also shows a higher mantoux positivity at 
95%. Dandapat et al study shows that mantoux positivity is seen in 94%.In 
Castro et al study mantoux positivity is 74%. 
 
Among 82 children with TB lymphadenitis malnutrition was seen in 
63 children (76.8%). Vimlesh seth et al study has shown that malnutrition is 
present in 88% of patients Balaji et al study conducted at ICH Madurai has 
shown a significant correlation of malnutrition with TB adenitis. 
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A positive contact history was obtained in 31 cases (37.8%) out of 82 
cases. A study conducted at ICH Chennai by Vijayasekaran et al., has shown 
that contact positivity is seen in 30.4% of patients and Vimlesh seth et al., 
study at AIIMS has shown a positive contact history in 19% of children. 
Ileana Puiu et al., study has a positive contact history in 87.3% of children. 
A low positive contact history indicates that there are still undetected cases 
of adult TB are prevalent in the community. 
 
In our study, 19 out of 82 cases with TB adenitis had abnormal 
radiological changes in x-ray chest (23.2%).  Ileana Puiu et al., study had 
abnormal radiological findings in 21.8%,   Jhaa et al study 16%, Polesky et 
al study 38%, Dandapat et al 35%, Castro et al study 18% of children with 
TB adenitis. 
 
Out of 82 cases who were started on either category 1 or 3 only 12 
had mild adverse symptoms. 7 children had nausea and vomiting, 5 had only 
nausea. None of these children had severe adverse symptoms such as 
jaundice, visual defects, etc.  Age distribution of adverse effects shows that 
these symptoms are less common in younger children.  Out of 12 children 
10 were above the age of 7 years.  Al Dossary et al., has shown that adverse 
events are seen in 1.2 % of children on DOTS.  Te Water Naude et al study 
has shown that none of the children had adverse events with DOTS. In 
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Tsakilidis D, et al study none of the child had any adverse events taking 
DOTS. 
 
Liver function tests were also analysed before and during the 
treatment.  In our study there was mild elevation of liver enzymes in 7 out of 
82 children with TB adenitis and 1 out 30 cases in pulmonary tuberculosis. 
None of the children had elevation of serum bilirubin. All the cases with 
elevated LFT were followed up and none of them required discontinuation 
of treatment. The enzyme levels became normal in all patients one month 
after completion of treatment. 
 
Treatment Outcome 
          In our study out of 82 children with TB adenitis, treatment was 
successful in 80 children. A repeat FNAC showed no evidence of 
tuberculosis in histopathological examination. In case of pulmonary 
tuberculosis out of 30 children treatment was successful in all the cases. Out 
of 30 children 5 were sputum positive for AFB. They became sputum 
negative at the end of intensive phase of therapy.  Over all the cure rate was 
98.2%. The cure rate was 97.5% with TB adenitis and 100% in children with 
pulmonary tuberculosis.    
 
 CK Indumathi et al study conducted at St.John’s Medical College 
Hospital Bangalore has shown a overall cure rate of 95% including 97% 
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cure rate in extra pulmonary TB and 94 % in pulmonary TB. Biddulph J et 
al study has 7 relapse cases out of 373 cases Gocmen A, et al has 1 relapse 
case out of 130 cases Tsakilidis D, et al had no cases of relapse out of 36 
children with TB. 
 
A recent study by Joseph L Mathew44 at PGI Chandigarh regarding 
the fixed dose combination therapy in childhood pulmonary tuberculosis. 
They concluded that there is no evidence of superiority of fixed-dose 
combination ATT over separate administration in terms of treatment 
effectiveness. 
 
There is a marginal benefit in terms of compliance, convenience and 
lower acquired drug resistance may be offset by unpredictable 
pharmacological properties of many FDC preparations. The choice of FDC 
or separate administration of ATT should be individualized rather than 
empiric.  
 
Recently a study at TB sanatorium regarding risk factors for MDR-TB 
in adults has found that  default of initial treatment is a major contributor to 
the risk of TB recurrence and thereby development of MDR - TB. 
 
In our study we have found that treatment with fixed dose 
combination of ATT using patient wise under RNTCP is efficacious in both 
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pulmonary TB and also in TB adenitis. Moreover there was no difficulty in 
procurement of these drugs, had very good compliance, and fewer adverse 
effects. 
 
In our study a correlation between the weight gain and treatment 
outcome was analysed. The results showed that there was a significant 
correlation between outcome and weight gain (0.979) in TB adenitis and 
(0.992) in case of pulmonary tuberculosis. 
 
We also analysed the correlation between rise in hemoglobin level 
and treatment outcome. It also showed a strong positive correlation (0.819) 
in children treated for TB adenitis and also in children treated for pulmonary 
tuberculosis (0.829). 
 
Weight gain and rise in hemoglobin level may be considered as one of 
the important indicators of good treatment outcome. Further studies may be 
required to confirm this correlation between rise in hemoglobin level and 
treatment outcome.  
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CONCLUSION 
 
 
The following conclusions are arrived from this study. 
1. The DOTS therapy using pediatric patient wise boxes under RNTCP is 
highly efficacious in childhood tuberculosis both in pulmonary and in TB 
adenitis. 
2. There are no major adverse effects associated with these fixed drug 
formulations of patient wise boxes. 
3. Malnutrition and anemia are more commonly associated with childhood 
tuberculosis both pulmonary and TB adenitis. 
4. Weight gain and rise in hemoglobin  have a strong  positive correlation 
with treatment outcome in both TB adenitis and pulmonary tuberculosis 
5. Weight gain and rise in hemoglobin level may be considered as one of 
the important indicators of good treatment outcome. 
 
The compliance of drug intake in these children was very good and 
had no difficulty in procurement of these drugs. There were fewer side 
effects. The school attendance and performance was not affected 
significantly.  
 
This good treatment outcome could be associated with the proper 
education about the disease and the treatment by the health care 
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.
professionals and to adherence of the therapy. This will in a large way help 
us in prevention of MDR-TB in children. 
 
 Thus more number of volunteers, health care workers, NGO’s, 
private practioners should be encouraged to participate in the successful 
implementation of this programme in the community.            
         
   
 
 
MASTER CHART TB ADENITIS 
s.no 
  Name  Age  Sex  W1 W2 mal cont  FNAC 1  FNAC 2 
X‐
ray 
1 
X‐
ray 
2  Hb 1  Hb 2 
LFT 
1 
LFT 
2  adv 
1  Bala chander  1  m  7 8.5 yes no  positive  negative  N  N  11.2 12.5 N  N  N 
2  sri kalyan  2  m  8 10 yes yes positive negative abn  N 7 10.8 N N N
3  sakthi priya  10  f  30 34 no yes  positive  positive  N  N  10.8 11.8 N  N  N 
4  raghuram  11  m  32 34 no no  positive  negative  N  N  11 12.5 N  N  N 
5  krithika  11  f  26 28 yes yes  positive  negative  abn  N  10.4 12 N  N  N 
6  dhanushi  2  f  7 8 yes yes positive negative N  N 9.8 11.2 N N N
7  monish  9  m  26 29 no no  positive  negative  N  N  8.8 10.6 N  N  N 
8  dinesh  9  m  16 20 yes no  positive  negative  N  N  11 12.5 N  N  Y 
9  manikandan  8  m  15 19 yes yes  positive  negative  N  N  10.8 12.8 N  N  N 
10  sakshi  3  f  8 10 yes yes positive negative N  N 11.2 13 N N N
11  sivakumar  7  m  20 22 no no  positive  negative  abn  N  12.4 12.8 N  N  Y 
12  dilli babu  3  m  8 12 yes no  positive  negative  N  N  10.8 11.8 N  N  N 
13  pushpa rani  3  f  7 10 yes no  positive  negative  N  N  12.4 13 N  N  N 
14  santosh  5  m  12 14 yes no positive negative N  N 11.2 12.8 N N N
15  manikandan  10  m  22 25 yes no  positive  positive  abn  N  12.8 12.5 N  N  Y 
16  dharan  10  m  24 27 yes no  positive  negative  N  N  12.4 12.9 N  N  N 
17  pavithra  2  f  8 10 yes yes  positive  negative  N  N  10.8 12.2 N  N  N 
18  arul raj  5  m  12 16 yes yes positive negative abn  N 8.6 11.2 N N N
19  sooriya  12  m  36 37 no no positive negative N  N 9 11.4 N N Y
20  yugendran  2  m  8 10 yes no  positive  negative  N  N  9.8 10.6 N  N  N 
21  gokul  8  m  15 20 yes no  positive  negative  N  N  9.6 12.5 N  N  N 
22  samuel  2  m  8 10 yes yes positive negative N  N 10.2 11.6 N N N
23  pasupathy  2  m  7 9 yes no positive negative abn  N 12.4 13.4 N N N
24  kishore  10  m  20 24 yes no  positive  negative  N  N  10.8 12.5 N  E  Y 
25  siva  7  m  20 22 no no  positive  negative  N  N  12.8 13.5 N  N  N 
26  jeyasri  1  f  7 9 yes yes positive negative abn  N 10.6 11.6 N N N
27  priyadarshini  8  f  22 25 no yes positive negative N  N 8.6 9.6 N N N
28  hemalatha  3  f  10 13 yes yes  positive  negative  N  N  9.8 10.2 N  N  N 
29  yona  8  f  18 22 yes no  positive  negative  N  N  10 10.8 N  N  Y 
30  mahalakshmi  12  f  26 28 yes no positive negative N  N 10.2 11.4 N N N
31  saravanan  4  m  12 15 yes no positive negative N  N 11.2 11.8 N E N
32  prabhavathy  2  f  10 12 no yes  positive  negative  abn  N  11.4 12.4 N  N  N 
33  jayaprasad  6  f  14 17 yes yes  positive  negative  N  N  10.2 12.6 N  E  N 
34  karthik  3  m  9 12 yes no  positive  negative  N  N  9.8 10.5 N  N  N 
35  sandhiya  8  f  18 23 yes no positive negative N  N 9.6 11.2 N E Y
36 
uma 
maheshwari  3  f  8 12 yes yes  positive  negative  N  N  10.4 12.6 N  N  N 
37  vetriselvi  12  f  36 38 no no  positive  negative  N  N  10.8 12.8 N  N  N 
38  aakash  8  m  22 25 no yes positive negative N  N 12.2 12.8 N N N
39  ashwini  3  m  8 11 yes yes  positive  negative  N  N  12.8 12.8 N  N  N 
40  manoj  2  m  7 10 yes no  positive  negative  abn  N  10.8 11.2 N  N  N 
41  anbalagan  12  m  24 27 yes no  positive  negative  N  N  12.8 13.5 N  N  Y 
42  santhiya  12  f  26 28 yes yes positive negative N  N 8.8 10.4 N N N
43  govindammal  4  m  10 14 yes no  positive  negative  N  N  9.6 10.2 N  E  N 
44  jennifer  12  m  28 32 yes yes  positive  negative  abn  N  10.4 11.2 N  E  N 
45  satish kumar  6  m  18 20 no no  positive  negative  abn  N  11.2 12 N  N  Y 
46  vignesh  10  m  20 24 yes no positive negative N  N 12.6 12.5 N N N
47  zubeida  10  f  22 26 yes no  positive  negative  N  N  12 12.5 N  N  Y 
48  manjula  7  m  20 22 no yes  positive  negative  N  N  11 12 N  N  N 
49  kamal  4  m  12 27 yes no  positive  negative  N  N  9.2 9.8 N  N  N 
50  nirmala  9  f  18 21 yes no positive negative abn  N 9.8 10.2 N N N
51  surendar  12  m  28 32 yes no positive negative N  N 12.4 13.5 N N N
52  ilavarasan  12  m  26 29 yes no  positive  negative  N  N  10.4 11 N  N  N 
53  vijay  8  m  18 22 yes no  positive  negative  N  N  10.8 11.8 N  N  N 
54  dhanalakshmi  12  f  30 31 yes no positive negative N  N 8.8 10.2 N N N
55  tamilarasan  2  m  8 11 yes yes positive negative N  N 7.8 10.4 N N N
56  vignesh  6  m  18 20 yes no  positive  negative  N  N  12.8 13 N  N  N 
57  deepa  12  f  35 38 no no  positive  negative  N  N  12 12.5 N  N  N 
58  suganthi  5  f  12 14 yes no positive negative abn  N 11.2 11.4 N N N
59  swetha  9  f  20 23 yes no positive negative N  N 9.6 10.2 N N N
60  elizabeth  12  f  34 36 no no  positive  negative  N  N  9.8 11 N  N  N 
61  jennifer  5  f  13 15 yes yes  positive  negative  N  N  10.4 11.2 N  N  N 
62  barath kumar  11  m  25 27 yes no positive negative abn  N 11 12.4 N E Y
63  prakash  12  m  29 31 yes no positive negative N  N 11.4 12.5 N N N
64  ramapriya  11  f  27 30 yes no  positive  negative  N  N  12 13.5 N  N  N 
65  sushmitha  3  f  14 17 no yes  positive  negative  N  N  12.8 13 N  N  N 
66  manikandan  11  m  25 28 yes no  positive  negative  N  N  9.8 10.8 N  N  N 
67  suriya  2  m  7 10 yes yes positive negative abn  N 9.6 10.2 N N Y
68  stella  11  m  32 34 no no  positive  negative  N  N  10.2 10.4 N  N  N 
69  deepa  9  f  19 22 yes no  positive  negative  N  N  11.2 11.8 N  N  N 
70  lavanya  11  f  25 28 yes no  positive  negative  N  N  12.4 12.5 N  N  N 
71  janani  8  f  24 25 no yes positive negative N  N 10.2 11 N N N
72  gayathri  9  f  18 19 yes yes  positive  negative  N  N  12.2 12.4 N  N  N 
73  kalyani  12  f  25 29 yes no  positive  negative  abn  N  9.8 10.6 N  N  N 
74  nivetha  9  f  18 22 yes yes  positive  negative  N  N  9.6 11.4 N  N  N 
75  preethika  7  f  16 20 yes no positive negative N  N 11 12 N N N
76  mohan  5  m  15 19 no no  positive  negative  abn  N  10.6 12.4 N  N  N 
77  amuldoss  5  m  12 15 yes yes  positive  negative  N  N  11.8 12.8 N  N  N 
78  vignesh  3  m  8 12 yes yes  positive  negative  N  N  12.4 12.5 N  N  N 
79  santosh  3  m  10 12 yes yes positive negative abn  N 12 12.8 N N N
80  jhansi  8  f  17 22 yes no  positive  negative  N  N  10.6 12.2 N  N  N 
81  karthik  9  m  22 24 yes no  positive  negative  abn  N  9.4 10.6 N  N  N 
82  gayathri  5  f  17 18 no yes  positive  negative  N  N  10.4 11.2 N  N  N 
 
 
 
 
MASTER CHART- PULMONARY TB 
 
Name  Age  Sex  W 1  W 2  mal cont  mantoux AFB 1    AFB 2 
X‐ray 
chest 1 
X‐ray 
chest 2  Hb 1 Hb 2 LFT 1  LFT 2 
adverse 
symptoms
1  nivetha  8  f  18  21  yes yes  negative  negative abnormal  normal  10.2 11.2 N  N  N 
2  sakthivel  12  m  32  34  no no  negative  negative abnormal  normal  11 12.4 N  N  N 
3  praveen  2  m  8  11  yes no  positive  negative abnormal  normal  10.2 12.8 N  N  Y 
4  revathy  8  f  14  15  yes no  positive  negative abnormal  normal  10.6 13.2 N  N  N 
5  nithya sri  9  f  18  19  yes yes  negative  negative abnormal  normal  11.2 12.8 N  N  N 
6  esthar  6  f  13  15  yes no  positive  negative abnormal  normal  12.8 13.2 N  N  N 
7  sonya  12  f  28  32  yes yes  positive  positive  negative  abnormal  normal  11.2 11.8 N  N  N 
8  ramarao  8  m  16  20  yes No  positive  positive  negative  abnormal  normal  12.6 12.8 N  N  N 
9  maheshwari  10  f  22  25  yes yes  negative  negative abnormal  normal  8.4 10.6 N  E  N 
10  harish kumar  5  m  15  18  yes no  negative  negative abnormal  normal  8.8 9.8 N  N  Y 
11  yuvasree  12  f  23  24  yes yes  positive  positive  negative  abnormal  normal  11.2 12.5 N  N  N 
12  venkat  1  m  7  9  yes yes  negative  negative abnormal  normal  9.8 11 N  N  N 
13  sriji  12  f  27  30  yes yes  negative  negative abnormal  normal  10.6 11.5 N  N  N 
14  tamini  2  m  8  9  yes no  negative  negative abnormal  normal  11.4 12.4 N  N  N 
15  karthiga  2  m  8  10  yes no  positive  negative abnormal  normal  10 11.4 N  N  Y 
16  meena  12  f  25  26  yes yes  positive  negative abnormal  normal  12.6 12.5 N  N  N 
17  shaheen  7  f  16  18  yes no  negative  negative abnormal  normal  12.8 13.1 N  N  Y 
18 
madhan 
kumar  4  m  12  13  yes yes  negative  negative abnormal  normal  10.6 11.4 N  N  N 
19  manish  9  m  16  19  yes yes  negative  positive  negative  abnormal  normal  10.6 12.5 N  N  N 
20  priya  6  f  13  15  no no  negative  negative abnormal  normal  11.6 12 N  N  N 
21  ashok  6  m  15  17  yes yes  negative  negative abnormal  normal  9.8 11 N  N  N 
22  harish kumar  5  m  15  18  yes no  negative  negative abnormal  normal  8.8 9.8 N  N  Y 
23  yuvasree  12  f  23  24  yes yes  positive  negative abnormal  normal  11.2 12.5 N  N  N 
24  venkat  1  m  7  9  yes yes  negative  negative abnormal  normal  9.8 11 N  N  N 
25  sriji  12  f  27  30  yes yes  negative  negative abnormal  normal  10.6 11.5 N  N  N 
26  tamini  2  m  8  9  yes no  negative  negative abnormal  normal  11.4 12.4 N  N  N 
27  karthiga  2  m  8  10  yes no  positive  negative abnormal  normal  10 11.4 N  N  Y 
28  meena  12  f  25  26  yes yes  positive  negative abnormal  normal  12.6 12.5 N  N  N 
29  shaheen  7  f  16  18  yes no  negative  negative abnormal  normal  12.8 13.1 N  N  Y 
30  manish  9  m  16  19  yes yes  negative  positive  negative  abnormal  normal  10.6 12.5 N  N  N 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
S. No. NAME     AGE   SEX 
 
SOCIOECONOMIC CLASS 
HISTORY     Yes / No DURATION 
1. Cough ?     
2. Fever ? 
3. Swelling in the neck ? 
4. Failure to gan Wt / Loss of Wt? 
5. Loss of appetite ? 
 
H / O Contact with Open case of TB?    Yes / No  
Any past H / O Tuberculosis?     Yes / No  
Category 
Treatment completed ?      Yes / No 
BCG Status ?       Yes / No 
 
Weight    Height    MAC 
 
Nutritional status 
 
INVESTIGATIONS: 
Mantoux 
Sputum  /  RGJ for AFB 1) 
    2) 
    3) 
FNAC 
X-ray Chest 
CT / MRI Chest 
ESR 
LFT  Sr. Billirubin 
 SGOT 
 SGPT 
 Alkaline Phosphatase 
Sr Uric acid 
Blood urea 
Sr. Creatinine 
 Hb % 
 Tc 
 Dc 
 Platelets 
 P/S 
HIV Status 
Parentral screening 
 
DIAGNOSIS: 
 
 
 
 
TREATMENT: 
Category  : 
Started on  : 
Completed on : 
PWB used 
 
FOLLOW UP: 
Weight 
Height 
MAC  
Nutritional status 
 
INVESTIGATIONS: 
Sputum  /  RGJ for AFB 1) 
    2) 
    3) 
FNAC 
X-ray Chest 
CT / MRI Chest 
ESR 
LFT  Sr. Billirubin 
 SGOT 
 SGPT 
 Alkaline Phosphatase 
Sr Uric acid 
Blood urea 
Sr. Creatinine 
 Hb % 
 Tc 
 Dc 
          Platelets 
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